Construction of prediction model for KRAS mutation status of colorectal cancer based on CT radiomics

被引:9
|
作者
Cao, Yuntai [1 ,2 ,3 ,4 ]
Zhang, Jing [5 ]
Huang, Lele [6 ]
Zhao, Zhiyong [7 ]
Zhang, Guojin [8 ,9 ]
Ren, Jialiang [10 ]
Li, Hailong [11 ]
Zhang, Hongqian [11 ]
Guo, Bin [11 ]
Wang, Zhan [11 ]
Xing, Yue
Zhou, Junlin [2 ,3 ,4 ]
机构
[1] Qinghai Univ, Affiliated Hosp, Dept Radiol, Tongren Rd 29, Xining 810001, Peoples R China
[2] Lanzhou Univ, Hosp 2, Dept Radiol, Cuiyingmen 82, Lanzhou 730030, Peoples R China
[3] Key Lab Med Imaging Gansu Prov, Lanzhou 730030, Peoples R China
[4] Gansu Int Sci & Technol Cooperat Base Med Imaging, Lanzhou 730030, Peoples R China
[5] Zunyi Med Univ, Affiliated Hosp 5, Zunyi 519100, Peoples R China
[6] Lanzhou Univ, Hosp 2, Dept Nucl Med, Lanzhou, Peoples R China
[7] Lanzhou Univ, Hosp 2, Dept Neurosurg, Lanzhou, Peoples R China
[8] Sichuan Acad Med Sci, Chengdu, Peoples R China
[9] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China
[10] GE Healthcare, Dept Pharmaceut Diag, Beijing, Peoples R China
[11] Qinghai Univ, Affiliated Hosp, Xining, Peoples R China
基金
中国国家自然科学基金;
关键词
KRAS mutation; Colorectal cancer; Radiomics; CT; Triphasic enhanced phase; K-RAS MUTATIONS; TEXTURE ANALYSIS; HETEROGENEITY; PET/CT; CARCINOMA; DIAGNOSIS; CETUXIMAB;
D O I
10.1007/s11604-023-01458-3
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
BackgroundIn this study, we used computed tomography (CT)-based radiomics signatures to predict the mutation status of KRAS in patients with colorectal cancer (CRC) and to identify the phase of radiomics signature with the most robust and high performance from triphasic enhanced CT.MethodsThis study involved 447 patients who underwent KRAS mutation testing and preoperative triphasic enhanced CT. They were categorized into training (n = 313) and validation cohorts (n = 134) in a 7:3 ratio. Radiomics features were extracted using triphasic enhanced CT imaging. The Boruta algorithm was used to retain the features closely associated with KRAS mutations. The Random Forest (RF) algorithm was used to develop radiomics, clinical, and combined clinical-radiomics models for KRAS mutations. The receiver operating characteristic curve, calibration curve, and decision curve were used to evaluate the predictive performance and clinical usefulness of each model.ResultsAge, CEA level, and clinical T stage were independent predictors of KRAS mutation status. After rigorous feature screening, four arterial phase (AP), three venous phase (VP), and seven delayed phase (DP) radiomics features were retained as the final signatures for predicting KRAS mutations. The DP models showed superior predictive performance compared to AP or VP models. The clinical-radiomics fusion model showed excellent performance, with an AUC, sensitivity, and specificity of 0.772, 0.792, and 0.646 in the training cohort, and 0.755, 0.724, and 0.684 in the validation cohort, respectively. The decision curve showed that the clinical-radiomics fusion model had more clinical practicality than the single clinical or radiomics model in predicting KRAS mutation status.ConclusionThe clinical-radiomics fusion model, which combines the clinical and DP radiomics model, has the best predictive performance for predicting the mutation status of KRAS in CRC, and the constructed model has been effectively verified by an internal validation cohort.
引用
收藏
页码:1236 / 1246
页数:11
相关论文
共 50 条
  • [41] CT imaging-based radiomics signatures improve prognosis prediction in postoperative colorectal cancer
    Kong, Yan
    Xu, Muchen
    Wei, Xianding
    Qian, Danqi
    Yin, Yuan
    Huang, Zhaohui
    Gu, Wenchao
    Zhou, Leyuan
    JOURNAL OF X-RAY SCIENCE AND TECHNOLOGY, 2023, 31 (06) : 1281 - 1294
  • [42] Quantitative Prediction of Microsatellite Instability in Colorectal Cancer With Preoperative PET/CT-Based Radiomics
    Li, Jiaru
    Yang, Ziyi
    Xin, Bowen
    Hao, Yichao
    Wang, Lisheng
    Song, Shaoli
    Xu, Junyan
    Wang, Xiuying
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] Commentary on "KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer"
    Benjamin, Laura E.
    CANCER RESEARCH, 2016, 76 (15) : 4309 - 4310
  • [44] Association of KRAS mutation with tumor deposit status and overall survival of colorectal cancer
    Meifang Zhang
    Wenwei Hu
    Kun Hu
    Yong Lin
    Zhaohui Feng
    Jing-Ping Yun
    Nan Gao
    Lanjing Zhang
    Cancer Causes & Control, 2020, 31 : 683 - 689
  • [45] Association of KRAS mutation with tumor deposit status and overall survival of colorectal cancer
    Zhang, Meifang
    Hu, Wenwei
    Hu, Kun
    Lin, Yong
    Feng, Zhaohui
    Yun, Jing-Ping
    Gao, Nan
    Zhang, Lanjing
    CANCER CAUSES & CONTROL, 2020, 31 (07) : 683 - 689
  • [46] The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
    Daeyoun David Won
    Jae Im Lee
    In Kyu Lee
    Seong-Taek Oh
    Eun Sun Jung
    Sung Hak Lee
    BMC Cancer, 17
  • [47] Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation
    Huang, Chi-Jung
    Huang, Shih-Hung
    Chien, Chih-Cheng
    Lee, Henry Hsin-Chung
    Yang, Shung-Haur
    Chang, Chun-Chao
    Lee, Chia-Long
    ONCOLOGY LETTERS, 2016, 12 (06) : 4427 - 4434
  • [48] KRAS mutation status, comorbidity, and mortality in patients with metastatic colorectal cancer in Denmark
    Ording, Anne Gulbech
    Oztuerk, Buket
    Spindler, Karen-Lise Garm
    Sorensen, Henrik Toft
    McCusker, Margaret
    Ehrenstein, Vera
    ACTA ONCOLOGICA, 2018, 57 (12) : 1727 - 1729
  • [49] The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status
    Akman, Tulay
    Oztop, Ilhan
    Baskin, Yasemin
    Unek, Ilkay Tugba
    Demir, Necla
    Ellidokuz, Hulya
    Yilmaz, Ahmet Ugur
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) : 96 - 102
  • [50] KRAS Mutation Status in Relation to Clinicopathological Characteristics of Romanian Colorectal Cancer Patients
    Avadanei, Elena-Roxana
    Caruntu, Irina-Draga
    Nuca, Irina
    Balan, Raluca Anca
    Lozneanu, Ludmila
    Giusca, Simona-Eliza
    Pricope, Diana Lavinia
    Dascalu, Cristina Gena
    Amalinei, Cornelia
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2025, 47 (02)